Tearsheet

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow


0 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 15%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 11%
Weak multi-year price returns
2Y Excs Rtn is -55%, 3Y Excs Rtn is -31%
 
1 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -34%
  
2 Low stock price volatility
Vol 12M is 31%
  
3 Megatrend and thematic drivers
Megatrends include Digital Health & Telemedicine, and Artificial Intelligence. Themes include Health Data Analytics, Remote Patient Monitoring, Show more.
  
0 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 15%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 11%
1 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -34%
2 Low stock price volatility
Vol 12M is 31%
3 Megatrend and thematic drivers
Megatrends include Digital Health & Telemedicine, and Artificial Intelligence. Themes include Health Data Analytics, Remote Patient Monitoring, Show more.
4 Weak multi-year price returns
2Y Excs Rtn is -55%, 3Y Excs Rtn is -31%

Valuation, Metrics & Events

CRVL Stock


Why The Stock Moved


Qualitative Assessment

AI Generated Analysis | Feedback

CorVel (CRVL) experienced a notable decline in its stock price, moving by approximately -21.5% between August 31, 2025, and December 15, 2025. This movement occurred amidst broader market shifts and specific company events, contributing to a larger year-to-date decrease in the stock's value.

1. Overvaluation and Market Correction: CorVel's stock was observed trading at a high price-to-earnings (P/E) ratio, which was more expensive than its sector average. An InvestingPro analysis in late 2024 also indicated that the stock was trading above its fair value, suggesting it may have been overvalued and ripe for a market correction throughout 2025.

2. Profit-Taking Following Significant Gains: After reaching an all-time high of $128.61 (post-split equivalent) in February 2025, investors likely engaged in profit-taking. The stock had experienced substantial price growth in the preceding year, making it prone to sell-offs as investors locked in gains.

Show more

Stock Movement Drivers

Return vs. Risk


Price Returns Compared

 202020212022202320242025Total [1]
Returns
CRVL Return21%96%-30%70%35%-37%143%
Peers Return6%29%11%30%-2%-9%75%
S&P 500 Return16%27%-19%24%23%16%111%

Monthly Win Rates [3]
CRVL Win Rate67%83%25%67%67%33% 
Peers Win Rate47%55%57%48%55%55% 
S&P 500 Win Rate58%75%42%67%75%73% 

Max Drawdowns [4]
CRVL Max Drawdown-46%-7%-37%-3%-9%-40% 
Peers Max Drawdown-38%-7%-13%-14%-17%-25% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 


[1] Cumulative total returns since the beginning of 2020
[2] Peers: AJG, CRD-A, CI, UNH, ELV.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/12/2025 (YTD)

How Low Can It Go

Unique KeyEventCRVLS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-37.1%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven59.0%34.1%
2022 Inflation ShockTime to BreakevenTime to Breakeven328 days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-50.7%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven102.9%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven217 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-20.9%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven26.4%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven175 days120 days
2008 Global Financial Crisis2008 Global Financial Crisis  
2008 Global Financial Crisis% Loss% Loss-66.6%-56.8%
2008 Global Financial Crisis% Gain to Breakeven% Gain to Breakeven199.8%131.3%
2008 Global Financial CrisisTime to BreakevenTime to Breakeven699 days1480 days

Compare to ADUS, CVS, CI, LH, DGX


In The Past

CorVel's stock fell -37.1% during the 2022 Inflation Shock from a high on 1/3/2022. A -37.1% loss requires a 59.0% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About CorVel (CRVL)

Better Bets than CorVel (CRVL)

Latest Trefis Analyses

Trade Ideas

Select past ideas related to CRVL. For more, see Trefis Trade Ideas.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
CRL_11142025_Dip_Buyer_FCFYield11142025CRLCharles River Laboratories InternationalDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
15.0%15.0%-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE11142025GDRXGoodRxDip BuyDB | CFO/Rev | Low D/EDip Buy with High Cash Flow Margins
Buying dips for companies with significant cash flows from operations and reasonable debt / market cap
-5.1%-5.1%-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG11142025ASTHAstrana HealthDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
9.0%9.0%-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG11142025SGRYSurgery PartnersDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
2.3%2.3%-1.4%
TFX_11072025_Dip_Buyer_FCFYield11072025TFXTeleflexDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
16.0%16.0%-5.1%
CRVL_1312022_Quality_Momentum_RoomToRun_10%01312022CRVLCorVelQualityQ | Momentum | UpsideQuality Stocks with Momentum and Upside
Buying quality stocks with strong momentum but still having room to run
-6.0%1.2%-25.1%
Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
CRL_11142025_Dip_Buyer_FCFYield11142025CRLCharles River Laboratories InternationalDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
15.0%15.0%-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE11142025GDRXGoodRxDip BuyDB | CFO/Rev | Low D/EDip Buy with High Cash Flow Margins
Buying dips for companies with significant cash flows from operations and reasonable debt / market cap
-5.1%-5.1%-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG11142025ASTHAstrana HealthDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
9.0%9.0%-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG11142025SGRYSurgery PartnersDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
2.3%2.3%-1.4%
TFX_11072025_Dip_Buyer_FCFYield11072025TFXTeleflexDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
16.0%16.0%-5.1%
CRVL_1312022_Quality_Momentum_RoomToRun_10%01312022CRVLCorVelQualityQ | Momentum | UpsideQuality Stocks with Momentum and Upside
Buying quality stocks with strong momentum but still having room to run
-6.0%1.2%-25.1%

Recent Active Movers

Recent Active Movers

More From Trefis

Peer Comparisons for CorVel

Peers to compare with:

Financials

CRVLAJGCRD-ACIUNHELVMedian
NameCorVel Arthur J.Crawford Cigna UnitedHe.Elevance. 
Mkt Price69.93255.3811.29274.70341.84359.07265.04
Mkt Cap3.679.50.673.1309.780.276.3
Rev LTM93413,0301,349261,220435,159194,820103,925
Op Inc LTM1352,68279-26,357-1,408
FCF LTM1011,767523,94417,3723,7672,767
FCF 3Y Avg821,972457,77318,9684,2953,133
CFO LTM1451,916925,29220,9584,9123,414
CFO 3Y Avg1162,133849,19722,4435,5193,826

Growth & Margins

CRVLAJGCRD-ACIUNHELVMedian
NameCorVel Arthur J.Crawford Cigna UnitedHe.Elevance. 
Rev Chg LTM10.4%15.6%4.4%20.9%10.5%12.0%11.2%
Rev Chg 3Y Avg10.6%15.3%4.1%13.6%11.4%8.4%11.0%
Rev Chg Q6.8%19.9%-2.9%11.2%12.2%12.3%11.7%
QoQ Delta Rev Chg LTM1.7%4.5%-0.7%2.7%2.9%2.9%2.8%
Op Mgn LTM14.5%20.6%5.8%-6.1%-10.3%
Op Mgn 3Y Avg13.1%19.5%5.6%-7.7%-10.4%
QoQ Delta Op Mgn LTM0.5%-0.5%0.2%--1.2%--0.1%
CFO/Rev LTM15.5%14.7%6.8%2.0%4.8%2.5%5.8%
CFO/Rev 3Y Avg13.7%19.1%6.3%4.4%5.8%3.1%6.0%
FCF/Rev LTM10.8%13.6%3.9%1.5%4.0%1.9%3.9%
FCF/Rev 3Y Avg9.7%17.7%3.4%3.8%4.9%2.4%4.3%

Valuation

CRVLAJGCRD-ACIUNHELVMedian
NameCorVel Arthur J.Crawford Cigna UnitedHe.Elevance. 
Mkt Cap3.679.50.673.1309.780.276.3
P/S4.36.10.40.30.70.40.6
P/EBIT29.4-7.79.211.98.59.2
P/E37.749.616.315.317.813.017.0
P/CFO27.541.55.814.514.914.714.8
Total Yield2.7%2.4%8.8%8.6%8.1%9.8%8.4%
Dividend Yield0.0%0.4%2.7%2.1%2.5%2.1%2.1%
FCF Yield 3Y Avg2.0%-9.3%9.0%4.5%4.7%4.7%
D/E0.0-0.60.40.30.40.4
Net D/E-0.0-0.40.30.2-0.00.2

Returns

CRVLAJGCRD-ACIUNHELVMedian
NameCorVel Arthur J.Crawford Cigna UnitedHe.Elevance. 
1M Rtn-5.7%-0.9%0.4%2.4%6.9%10.8%1.4%
3M Rtn-18.3%-13.9%7.0%-8.8%-1.8%15.8%-5.3%
6M Rtn-33.4%-19.0%14.3%-12.5%11.2%-5.6%-9.1%
12M Rtn-40.4%-9.5%2.3%-0.5%-32.7%-4.0%-6.8%
3Y Rtn49.6%39.6%115.0%-12.5%-31.6%-26.2%13.6%
1M Excs Rtn-9.1%0.4%-1.3%2.4%1.8%10.5%1.1%
3M Excs Rtn-18.7%-14.7%6.3%-10.2%-4.3%14.4%-7.3%
6M Excs Rtn-47.7%-33.2%0.1%-26.8%-3.0%-19.9%-23.3%
12M Excs Rtn-54.5%-22.3%-9.3%-23.1%-51.2%-19.2%-22.7%
3Y Excs Rtn-31.4%-38.2%28.1%-86.2%-107.0%-102.6%-62.2%

Financials

Segment Financials

Revenue by Segment

$ Mil20252024202320222021
Patient management services530479424369387
Network solutions services265240222184205
Total795719646553592


Price Behavior

Short Interest

Short Interest: As Of Date11282025
Short Interest: Shares Quantity564,715
Short Interest: % Change Since 11152025-3.8%
Average Daily Volume163,453
Days-to-Cover Short Interest3.45
Basic Shares Quantity51,314,000
Short % of Basic Shares1.1%

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/4/2025-0.8%2.0%-9.1%
8/5/20250.8%2.5%-1.9%
5/22/2025-3.7%-2.9%-8.6%
2/4/20257.5%1.2%-7.1%
11/5/202411.0%13.7%11.3%
5/22/2024-1.6%-14.3%-11.4%
1/30/2024-0.8%-2.0%2.8%
10/31/20230.5%2.0%7.7%
...
SUMMARY STATS   
# Positive9108
# Negative10911
Median Positive1.9%2.6%6.9%
Median Negative-2.3%-3.9%-5.3%
Max Positive13.7%13.7%11.3%
Max Negative-6.7%-14.3%-20.9%

SEC Filings

Expand for More

Report DateFiling DateFiling
93020251106202510-Q 9/30/2025
6302025807202510-Q 6/30/2025
3312025523202510-K 3/31/2025
12312024206202510-Q 12/31/2024
93020241107202410-Q 9/30/2024
6302024801202410-Q 6/30/2024
3312024524202410-K 3/31/2024
12312023201202410-Q 12/31/2023
93020231102202310-Q 9/30/2023
6302023803202310-Q 6/30/2023
3312023526202310-K 3/31/2023
12312022202202310-Q 12/31/2022
93020221103202210-Q 9/30/2022
6302022804202210-Q 6/30/2022
3312022527202210-K 3/31/2022
12312021203202210-Q 12/31/2021